Everolimus: 24 months analysis of Tuberous Sclerosis Complex (TSC)
Page last updated: 30 June 2017
Drug utilisation sub-committee (DUSC)
February 2017
Abstract
Purpose
The PBAC requested a 24 month review of everolimus for tuberous sclerosis complex (TSC), which is a genetic disorder characterised by the growth of numerous noncancerous tumours in many parts of the body. Everolimus was first PBS-listed for this indication on 1 December 2013.
Data Source / methodology
The analyses use data from the Department of Human Services (DHS) Medicare Supplied prescriptions database and the DHS Authority approvals database from December 2013 to September 2016.
Key Findings
- Since listing on the PBS on 1 December 2013, 322 patients have been supplied everolimus for TSC.
- The use of 2.5 mg and 5 mg prescriptions has been higher than estimated, and the use of 10 mg prescriptions has been lower than estimated.
